Colorectal Cancer

The FDA approved two oncology regimens on Jan. 16.

Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.

Individuals with negative colonoscopy screening results had lower long-term risk for colorectal cancer and related mortality, with researchers suggesting the recommended 10-year rescreening interval may be extended for this population.

Improvement in adenoma detection rate among physicians with a baseline rate of less than 26% was significantly associated with decreased patient risk for colorectal cancer, according to results of an observational study conducted in Poland.

Although most older adults supported guidelines to discontinue colon cancer screening after age 75 years, a “sizable minority” did not, regardless of estimated life expectancy, according to a study published in JAMA Network Open.

As 2024 comes to a close, Healio is pleased to present our most widely read oncology and hematology content from the past 12 months.

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.

The FDA granted an encorafenib-led combination accelerated approval for the treatment of certain patients with metastatic colorectal cancer.

According to a new report from the National Academies of Sciences, Engineering, and Medicine, or NASEM, moderate alcohol consumption may lower the risk for death from all causes and CVD.